Literature DB >> 17855094

Ascertainment of breast cancer by the Scottish Cancer Registry: an assessment based on comparison with five independent breast cancer trials databases.

David H Brewster1, Diane L Stockton.   

Abstract

Completeness of ascertainment of breast cancer cases by the Scottish Cancer Registry (SCR) was assessed by independent comparison with five clinical trials databases, comprising 2621 patients and spanning the total period of diagnosis 1978-2000. Overall, ascertainment was estimated to exceed 98%, although 0.3% of matched cases were misclassified as carcinoma in situ by the SCR. These results support the validity of national estimates of incidence of, and survival from, breast cancer in Scotland.

Entities:  

Mesh：

Year:  2007        PMID： 17855094     DOI： 10.1016/j.breast.2007.07.044

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


  11 in total

1.  Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study.

Authors:  Anushri Chitkara; Ines Mesa-Eguiagaray; Sarah H Wild; Peter S Hall; David A Cameron; Andrew H Sims; Jonine D Figueroa
Journal:  Breast Cancer Res Treat       Date:  2022-09-18       Impact factor: 4.624

2.  Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype.

Authors:  Ines Mesa-Eguiagaray; Sarah H Wild; Sheila M Bird; Linda J Williams; David H Brewster; Peter S Hall; Jonine D Figueroa
Journal:  Breast Cancer Res Treat       Date:  2022-06-01       Impact factor: 4.624

3.  Does the 'Scottish effect' apply to all ethnic groups? All-cancer, lung, colorectal, breast and prostate cancer in the Scottish Health and Ethnicity Linkage Cohort Study.

Authors:  Raj S Bhopal; Narinder Bansal; Markus Steiner; David H Brewster
Journal:  BMJ Open       Date:  2012-09-25       Impact factor: 2.692

4.  The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study.

Authors:  K Shafique; R Oliphant; D S Morrison
Journal:  Br J Cancer       Date:  2012-07-03       Impact factor: 7.640

5.  Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening.

Authors:  E O Fourkala; A Gentry-Maharaj; M Burnell; A Ryan; R Manchanda; A Dawnay; I Jacobs; M Widschwendter; U Menon
Journal:  Br J Cancer       Date:  2012-05-17       Impact factor: 7.640

6.  Burn injury, gender and cancer risk: population-based cohort study using data from Scotland and Western Australia.

Authors:  Janine M Duke; Jacqui Bauer; Mark W Fear; Suzanne Rea; Fiona M Wood; James Boyd
Journal:  BMJ Open       Date:  2014-01-17       Impact factor: 2.692

7.  Ascertainment of cancer in longitudinal research: The concordance between the Rotterdam Study and the Netherlands Cancer Registry.

Authors:  Kimberly D van der Willik; Rikje Ruiter; Frank J A van Rooij; Jolande Verkroost-van Heemst; Sander J Hogewoning; Karin C A A Timmermans; Otto Visser; Sanne B Schagen; M Arfan Ikram; Bruno H Ch Stricker
Journal:  Int J Cancer       Date:  2019-11-07       Impact factor: 7.396

8.  Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data.

Authors:  Ines Mesa-Eguiagaray; Sarah H Wild; Philip S Rosenberg; Sheila M Bird; David H Brewster; Peter S Hall; David A Cameron; David Morrison; Jonine D Figueroa
Journal:  Br J Cancer       Date:  2020-06-19       Impact factor: 7.640

9.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Authors:  H M Colhoun
Journal:  Diabetologia       Date:  2009-07-15       Impact factor: 10.122

10.  Time from first presentation in primary care to treatment of symptomatic colorectal cancer: effect on disease stage and survival.

Authors:  P Murchie; E A Raja; D H Brewster; N C Campbell; L D Ritchie; R Robertson; L Samuel; N Gray; A J Lee
Journal:  Br J Cancer       Date:  2014-07-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.